{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T16:19:40Z","timestamp":1700237980086},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2003,2,1]]},"DOI":"10.1038\/sj.leu.2402726","type":"journal-article","created":{"date-parts":[[2003,2,18]],"date-time":"2003-02-18T16:50:43Z","timestamp":1045587043000},"page":"319-322","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts"],"prefix":"10.1038","volume":"17","author":[{"given":"V","family":"Ribrag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Suzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Ravoet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Feremans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Guerci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Dreyfus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Vantelon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,2,18]]},"reference":[{"key":"BF2402726_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1365-2141.1985.tb07329.x","volume":"59","author":"GJ Mufti","year":"1985","unstructured":"Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D . Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425\u2013433.","journal-title":"Br J Haematol"},{"key":"BF2402726_CR2","first-page":"389","volume":"1","author":"DG Oscier","year":"1987","unstructured":"Oscier DG . Myelodysplastic syndromes. Clin Haematol 1987; 1: 389\u2013426.","journal-title":"Clin Haematol"},{"key":"BF2402726_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00282-996-0363-7","volume":"38","author":"P Fenaux","year":"1996","unstructured":"Fenaux P . Myelodysplastic syndromes. Hematol Cell Ther 1996; 38: 363\u2013380.","journal-title":"Hematol Cell Ther"},{"key":"BF2402726_CR4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood.V88.1.358.358","volume":"88","author":"L Sutton","year":"1996","unstructured":"Sutton L, Chastang C, Ribaud P, Jouet JP, Kuentz M, Attal M, Rieffers J, Tigaud JM, Rio B, Dauriac C, Legros F, Dreyfus F, Lioure B, Troussard X, Milpied M, Witz F, Oriol P, Cahn JY, Michallet M, Gluckman E, Ifrah N, Pico JL, Vilmer E, Leblond V . Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long term study of 71 patients. Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle. Blood 1996; 88: 358\u2013365.","journal-title":"Blood"},{"key":"BF2402726_CR5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V82.2.677.677","volume":"82","author":"JE Anderson","year":"1993","unstructured":"Anderson JE, Appelbaum FR, Fisher LD, Schoch G, Shulman H, Anasetti C, Besinger WI, Bryant E, Buckner CD, Doney K, Martin PJ, Sander JE, Sullivan KM, Thomas ED, Witherspoon RP, Hansen JA, Storb R . Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677\u2013681.","journal-title":"Blood"},{"key":"BF2402726_CR6","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1182\/blood.V98.8.2326","volume":"98","author":"T De Witte","year":"2001","unstructured":"De Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Boogaerts M, Zittoun R, Gratwohl A, Zwierzina H, Hagemeijer A, Willemze R . Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplstic syndromes or acute myeloid leukemia following MDS. Blood 2001; 98: 2326\u201323331.","journal-title":"Blood"},{"key":"BF2402726_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1046\/j.1365-2141.1997.2973114.x","volume":"98","author":"E Wattel","year":"1997","unstructured":"Wattel E, De Botton S, Lao JL, Pruedhomme C, Lepelley P, Bauters F, Fenaux P . Long-term follow-up of de novo myelodysplatic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. Br J Haematol 1997; 98: 983\u2013991.","journal-title":"Br J Haematol"},{"key":"BF2402726_CR8","first-page":"126","volume":"14","author":"BD Cheson","year":"1987","unstructured":"Cheson BD, Simon R . Low-dose ara-C in acute non-lymphocytic leukemia and myelodysplastic syndrome: a review of 20 years\u2019 experience. Semin Oncol 1987; 14: 126\u2013133.","journal-title":"Semin Oncol"},{"key":"BF2402726_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/BF01703109","volume":"65","author":"KB Miller","year":"1992","unstructured":"Miller KB, Kyungmann K, Morison FS, Winter JN, Bennet JM, Neiman RS, Head DR, Gassileth PA, O\u2019connell MJ . The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Ann Hematol 1992; 65: 162\u2013168.","journal-title":"Ann Hematol"},{"key":"BF2402726_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1046\/j.1365-2141.2000.01825.x","volume":"108","author":"C Denzlinger","year":"2000","unstructured":"Denzlinger C, Bowen D, Benz D, Gelly K, Burgger W, Kanz L . Low-dose melphalan induces favorable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukemia. Br J Haematol 2000; 108: 93\u201395.","journal-title":"Br J Haematol"},{"key":"BF2402726_CR11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","volume":"18","author":"P Wijermans","year":"2000","unstructured":"Wijermans P, Lobbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A . Low-dose 5-Aza-2\u2032-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956\u2013962.","journal-title":"J Clin Oncol"},{"key":"BF2402726_CR12","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood.V80.10.2604.2604","volume":"80","author":"M Andreeff","year":"1992","unstructured":"Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Mark PA . Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 1992; 80: 2604\u20132609.","journal-title":"Blood"},{"key":"BF2402726_CR13","first-page":"26","volume":"35","author":"M Beran","year":"1998","unstructured":"Beran M, Kantarjian H . Topotecan in the treatment of hematologic malignancies. Semin Hematol 1998; 35: 26\u201331.","journal-title":"Semin Hematol"},{"key":"BF2402726_CR14","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","volume":"17","author":"M Bearn","year":"1999","unstructured":"Bearn M, Estey E, O\u2019Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreef M, Vey N, Pierce SR, Hayes K, Chaun Wong G, Keating M, Kantarjian H . Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999; 17: 2819\u20132830.","journal-title":"J Clin Oncol"},{"key":"BF2402726_CR15","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"Cheson BD, Bennet JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, L\u00f6venberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL . Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671\u20133674.","journal-title":"Blood"},{"key":"BF2402726_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/jnci\/86.6.446","volume":"86","author":"D Abigerges","year":"1994","unstructured":"Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, H\u00e9rait P, Gandia D . Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 446\u2013449.","journal-title":"J Natl Cancer Inst"},{"key":"BF2402726_CR17","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennet JM . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079\u20132088.","journal-title":"Blood"},{"key":"BF2402726_CR18","first-page":"3","volume":"35","author":"SG Arbuck","year":"1998","unstructured":"Arbuck SG, Takimoto CH . An overview of topoisomerase I targeting agents. Semin Hematol 1998; 35: 3\u201312.","journal-title":"Semin Hematol"},{"key":"BF2402726_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF00685611","volume":"32","author":"Y Pommier","year":"1993","unstructured":"Pommier Y . DNA topoisomerase I and II in cancer chemotherapy: update and perspective. Cancer Chemother Pharmacol 1993; 32: 103\u2013108.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2402726_CR20","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1200\/JCO.1990.8.11.1907","volume":"8","author":"R Ohno","year":"1990","unstructured":"Ohno R, Okada K, Masaoka T, Kuramato A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K . An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990; 8: 1907\u20131912.","journal-title":"J Clin Oncol"},{"key":"BF2402726_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s002770100313","volume":"80","author":"N Niitsu","year":"2001","unstructured":"Niitsu N, Iijima K, Chizuka A . Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin\u2019s lymphoma: a pilot study. Ann Hematol 2001; 80: 411\u2013416.","journal-title":"Ann Hematol"},{"key":"BF2402726_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1023\/A:1008368905546","volume":"11","author":"T Saotome","year":"2000","unstructured":"Saotome T, Takagi T, Sakai C, Kumagai K, Tamaru J . Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin\u2019s lymphoma. Ann Oncol 2000; 11: 115\u2013116.","journal-title":"Ann Oncol"},{"key":"BF2402726_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/bjc.1994.394","volume":"70","author":"H Tsuda","year":"1994","unstructured":"Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, Ohashi Y, Ota K . Treatment of adult T-cell leukemia-lymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer 1994; 70: 771\u2013774.","journal-title":"Br J Cancer"},{"key":"BF2402726_CR24","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1200\/JCO.1993.11.11.2194","volume":"11","author":"ML Rothenberg","year":"1993","unstructured":"Rothenberg ML, Kuhn JG, Burris HA 3rd, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI . Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194\u201321204.","journal-title":"J Clin Oncol"},{"key":"BF2402726_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1200\/JCO.1995.13.1.210","volume":"13","author":"D Abigerges","year":"1995","unstructured":"Abigerges D, Chabot GG, Armand JP, H\u00e9rait P, Gouyette A, Gandia D . Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210\u2013221.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2402726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402726","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:23:44Z","timestamp":1648761824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2402726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,1]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2,1]]}},"alternative-id":["BF2402726"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2402726","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,1]]},"assertion":[{"value":"7 May 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}